Status: Recruiting
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.
Participants needed: 88
Trial details
Phase: Phase 3Age: 15+Biological sex: AllType: InterventionalSponsor: Shoichi Maruyama MD PhDUpdated: Feb 11, 2025Locations: 18
Eligibility criteria
Patients who undergo kidney biopsy and are diagnosed as having idiopathic membra... [+5]
Patients with primary nephrotic syndrome other than membranous nephropathy (IgA... [+13]